Maria Ekblad
Directeur Technique/Scientifique/R&D chez FOLLICUM AB (PUBL)
Provenance du réseau au premier degré de Maria Ekblad
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden.
13
| Public Company | Pharmaceuticals: Major | 13 |
| Subsidiary | Pharmaceuticals: Major | 12 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Maria Ekblad via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| PROBI AB | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
| PCI BIOTECH HOLDING ASA | Biotechnology | Director/Board Member | |
| ARBONA AB | Financial Conglomerates | Founder Director/Board Member | |
AspenTech Norway AS
 AspenTech Norway AS Packaged SoftwareTechnology Services AspenTech Norway AS engages developing industrial analytics solutions for optimizing product development and manufacturing processes by leveraging advanced sensor analysis. The firm’s products include unscramble analytics suite, unscramble, unscramble HIS, process pulse and training. It also offers solutions like batch monitoring, blend monitoring, continuous manufacturing, continuous feed monitoring (PIONA), drying optimization, fermentation monitoring, machine vision, quality and reaction monitoring. The company was founded on July 18, 1984 and is headquartered in Oslo, Norway. | Packaged Software | Director/Board Member | |
Ferrosan ApS
 Ferrosan ApS Pharmaceuticals: OtherHealth Technology Ferrosan ApS manufactures and sells pharmaceutical products. Its products include herbal medicine, natural remedies, food supplements, and medical devices. The company was founded by Niels Jacob Herman Weitzmann in 1920 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Other | Corporate Officer/Principal | |
| University of Uppsala | College/University | Graduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Corporate Officer/Principal | |
| University of Lund | College/University | Director/Board Member Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree | |
| Scandinavian International Management Institute | College/University | Masters Business Admin | |
| University of Gothenburg | College/University | Doctorate Degree Doctorate Degree | |
| NATTOPHARMA ASA | Pharmaceuticals: Major | Director/Board Member | |
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Sales & Marketing | |
| XSPRAY PHARMA AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| WNTRESEARCH AB | Pharmaceuticals: Other | Chief Executive Officer Chairman | |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nycomed AB
 Nycomed AB Pharmaceuticals: MajorHealth Technology Nycomed AB With a broad portfolio of products and a powerful pipeline, they work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. Nycomed engaged in all aspects of a product's life, from research and development to customer relations. They also work closely with innovative research-based companies, constantly looking for products with real promise for patients. They believe that everything do matters to someone. So they work carefully to make sure they get what they do right. They focus on results and respond quickly to the needs of patients and healthcare providers, giving them the best possible experience from working with clients. By doing this, they can achieve vision of being the preferred pharmaceutical company. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Rechon Life Science AB
 Rechon Life Science AB Pharmaceuticals: MajorHealth Technology Rechon Life Science AB manufactures medicines. It specializes in aseptic injectables and sprays for nasal and oral administration. The firm's products include Iron Sucrose Injection. The firm's services include formulation and analytical development, clinical trial, stability studies, and storage and distritutions. The company is headquartered in Limhamn, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
Pharmaorigin A/S
 Pharmaorigin A/S Pharmaceuticals: MajorHealth Technology Pharmaorigin ApS is a holding company that provides medical treatment. It offers medication for prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia. The company was founded by Lars Heslet on November 14, 2005 and is headquartered in H?rsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
| Magnus Innovasjon AS | Chief Executive Officer | ||
| GUARD THERAPEUTICS INTERNATIONAL AB | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
| CIRCIO HOLDING ASA | Biotechnology | Chief Executive Officer | |
| Ideonfonden AB | Director/Board Member Chief Executive Officer | ||
| Accequa AB | Director/Board Member Founder | ||
| ARCEDE PHARMA AB | Miscellaneous Commercial Services | Director/Board Member | |
| University of Detroit Mercy School of Law | College/University | Graduate Degree | |
| GABATHER AB | Pharmaceuticals: Major | Director/Board Member Founder Director of Finance/CFO | |
| ICONOVO AB | Pharmaceuticals: Major | Chairman | |
CytoVac AS
 CytoVac AS BiotechnologyHealth Technology CytoVac AS manufactures pharmaceuticals. The private company is based in Hørsholm, Denmark. The Danish company was founded in 2008. The CEO is Lone Dahl Andersen. | Biotechnology | Chief Executive Officer | |
| Basilea Pharmaceuticals A/S | Corporate Officer/Principal | ||
| Portendo Standoff Detection AB | Founder | ||
| INVENT MEDIC SWEDEN AB | Medical Specialties | Chairman Director of Finance/CFO | |
| Ceratmo AB | Director/Board Member | ||
| CYXONE AB | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member Director/Board Member Chief Executive Officer | |
| LIPUM AB | Biotechnology | Director/Board Member Chairman | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Director/Board Member Founder | |
Asgard Therapeutics AB
 Asgard Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Asgard Therapeutics AB engages in biotechnological research and development activities. It is in use of cellular reprogramming in cancer immunotherapy, which forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. The company was founded by Filipe Pereira, Cristiana Pires and Fábio Rosa in 2018 and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
| MS Persson Consulting AB | Director/Board Member | ||
| Galecto Biotech AB | Founder Founder | ||
Inprother ApS
 Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | Biotechnology | Chief Executive Officer | |
| Accequa GmbH | Director/Board Member Director/Board Member | ||
Advokatfirmaet Nova Da
 Advokatfirmaet Nova Da Miscellaneous Commercial ServicesCommercial Services Advokatfirmaet Nova Da is a medium-sized law firm based in Oslo, Norway with additional offices in Volda and Bodø. The firm has been providing high-quality legal assistance since 1995 and offers a free case evaluation. Nova prides itself on its innovative approach while maintaining a strong foundation of expertise and experience. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Mylifeproducts AS | Chairman | ||
| Aptahem Finans AB | Founder | ||
| Serstech Förvaltning AB | Founder | ||
| Mikeoo Holding AB | Founder | ||
| Holy Plantmedix AB | Founder | ||
Melius Pharma AB
 Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Pharmaceuticals: Major | Director/Board Member | |
| BRAIN+ A/S | Packaged Software | Director/Board Member |
Statistiques
Internationale
| Suède | 31 |
| Danemark | 11 |
| Norvège | 8 |
| Suisse | 3 |
| Etats-Unis | 2 |
Sectorielle
| Health Technology | 25 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Technology Services | 3 |
| Finance | 2 |
Opérationnelle
| Director/Board Member | 147 |
| Corporate Officer/Principal | 41 |
| Chief Executive Officer | 37 |
| Chairman | 35 |
| Founder | 21 |
Relations les plus connectées
- Bourse
- Insiders
- Maria Ekblad
- Connexions Sociétés
